Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Ott

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Menopause (New York, N.Y.)|September 28, 2016
Long-term bisphosphonates: primum non nocereSusan M Ott
The New England Journal of Medicine|October 5, 2012
Vitamin D dose requirements for fracture preventionSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|April 9, 2008
Reproductive hormones and skeletal health in young womenSusan M Ott
Cleveland Clinic Journal of Medicine|April 3, 2013
What should be the interval between bone density screenings?Susan M Ott
Current Opinion in Nephrology and Hypertension|April 26, 2012
Bone disease in CKDSusan M Ott
Annals of Internal Medicine|January 4, 2021
In women, bisphosphonate use for ≥3 years vs. <3 months was linked to increased atypical femur fracture riskSusan M Ott
JAMA|May 10, 2007
Use of alendronate after 5 years of treatmentSusan M Ott
The New England Journal of Medicine|May 26, 2016
Postmenopausal OsteoporosisSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|December 7, 2005
Sclerostin and Wnt signaling--the pathway to bone strengthSusan M Ott
Current Osteoporosis Reports|May 4, 2017
Renal Osteodystrophy-Time for Common NomenclatureSusan M Ott
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Menopause (New York, N.Y.)|September 28, 2016
Long-term bisphosphonates: primum non nocereSusan M Ott
The New England Journal of Medicine|October 5, 2012
Vitamin D dose requirements for fracture preventionSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|April 9, 2008
Reproductive hormones and skeletal health in young womenSusan M Ott
Cleveland Clinic Journal of Medicine|April 3, 2013
What should be the interval between bone density screenings?Susan M Ott
Current Opinion in Nephrology and Hypertension|April 26, 2012
Bone disease in CKDSusan M Ott
Annals of Internal Medicine|January 4, 2021
In women, bisphosphonate use for ≥3 years vs. <3 months was linked to increased atypical femur fracture riskSusan M Ott
JAMA|May 10, 2007
Use of alendronate after 5 years of treatmentSusan M Ott
The New England Journal of Medicine|May 26, 2016
Postmenopausal OsteoporosisSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|December 7, 2005
Sclerostin and Wnt signaling--the pathway to bone strengthSusan M Ott
Current Osteoporosis Reports|May 4, 2017
Renal Osteodystrophy-Time for Common NomenclatureSusan M Ott
Pageof 9